Table 2.

Median (IQR) anti-N and anti-S titres according to clinical classification of participants

	Oligo/asymptomatic*	Symptomatic†	Hospital admitted	Total
Anti-spike serology
First follow-up  N=149	14.6 (10.0, 85.0)	69.5 (33.9, 100.0)	232.0 (112.0, 256.0)	71.7 (30.0, 112.0)
Second follow-up  N=128	18.1 (10.0, 86.0)	66.0 (28.6, 136.0)	134.5 (75.0, 208.0)	72.9 (29.1, 144.0)
Last follow-up  N=130	16.0 (7.2, 92.0)	72.2 (27.4, 242.0)	116.0 (82.9, 216.0)	85.0 (29.1, 190.0)
Antinucleocapside serology
First follow-up  N=149	3.05 (1.19, 4.93)	3.05 (1.19, 4.93)	4.55 (2.89, 6.02)	3.11 (1.39, 5.00)
Second follow-up  N=128	1.07 (0.36, 4.00)	1.33 (0.56, 2.40)	2.44 (1.75,4.22)	1.7 (0.62, 2.89)
Last follow-up  N=130	0.34 (0.15, 0.88)	0.74 (0.31, 1.60)	1.34 (0.77, 2.38)	0.8 (0.33, 1.71)

*Oligosymptomatic patients are those with symptoms enduring for less than 3 days or with only one symptom (anosmia/ageusia or asthenia).

†Symptomatic patients are those with one more symptom lasting at least 3 days and without any hospital admission.